APAC CIOOutlook

Advertise

with us

  • Technologies
      • Artificial Intelligence
      • Big Data
      • Blockchain
      • Cloud
      • Digital Transformation
      • Internet of Things
      • Low Code No Code
      • MarTech
      • Mobile Application
      • Security
      • Software Testing
      • Wireless
  • Industries
      • E-Commerce
      • Education
      • Logistics
      • Retail
      • Supply Chain
      • Travel and Hospitality
  • Platforms
      • Microsoft
      • Salesforce
      • SAP
  • Solutions
      • Business Intelligence
      • Cognitive
      • Contact Center
      • CRM
      • Cyber Security
      • Data Center
      • Gamification
      • Procurement
      • Smart City
      • Workflow
  • Home
  • CXO Insights
  • CIO Views
  • Vendors
  • News
  • Conferences
  • Whitepapers
  • Newsletter
  • Awards
Apac
  • Artificial Intelligence

    Big Data

    Blockchain

    Cloud

    Digital Transformation

    Internet of Things

    Low Code No Code

    MarTech

    Mobile Application

    Security

    Software Testing

    Wireless

  • E-Commerce

    Education

    Logistics

    Retail

    Supply Chain

    Travel and Hospitality

  • Microsoft

    Salesforce

    SAP

  • Business Intelligence

    Cognitive

    Contact Center

    CRM

    Cyber Security

    Data Center

    Gamification

    Procurement

    Smart City

    Workflow

Menu
    • Cyber Security
    • Hotel Management
    • Workflow
    • E-Commerce
    • Business Intelligence
    • MORE
    #

    Apac CIOOutlook Weekly Brief

    ×

    Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Apac CIOOutlook

    Subscribe

    loading

    THANK YOU FOR SUBSCRIBING

    Individualizing Drug doses Amongst Patients of Depression

    Genetic variations can be responsible for the failure of drugs such as Serotonin reuptake inhibitors (SSRIs) which are used to treat depression. 

    Individualizing Drug doses Amongst Patients of Depression

    By

    Apac CIOOutlook | Thursday, January 01, 1970

    Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

    Genetic variations can be responsible for the failure of drugs such as Serotonin reuptake inhibitors (SSRIs) which are used to treat depression. According to a new study published in the American Journal of Psychiatry, variations within genes and enzymes such as the CYP2C19 are responsible for differences in bioavailability of SSRIs like escitalopram amongst patients. Escitalopram’s dosage is prescribed to patients based on their specific genetic constitution, and this greatly improves therapeutic outcomes.

    SSRIs are commonly used for the treatment of depression, but several patients react and respond differently to them. Among all the SSRIs, escitalopram was quite frequently used in the clinics to treat patients with depression. But the use of this drug has become quite limited as the response to the drug was not as expected, with many patients developing adverse reactions after the discontinuation of treatment.

    To understand if a patient will be able to respond properly to a drug therapy, many researchers have been attempting to establish genetic biomarkers that can predict how a patient would respond. People with the variant of genes usually have increased enzyme expression and low blood levels of escitalopram. Studies show that one-third of the patients tested for drug levels have either too high or too low levels of drugs in their blood.

    Thus individualizing doses, genotyping of CYP2C19 could be of considerable clinical value and can give better all-round anti-depressive effect to a patient.

    More in News

    Real-Time Insights Fueling Smarter Brand Strategies

    Real-Time Insights Fueling Smarter Brand Strategies

    Transforming Retail: The Impact of VR and AR in Asia Pacific

    Transforming Retail: The Impact of VR and AR in Asia Pacific

    Enhancing Customer Satisfaction through Omni-Channel Payments

    Enhancing Customer Satisfaction through Omni-Channel Payments

    AI's Role in Apac's Digital Transformation Journey

    AI's Role in Apac's Digital Transformation Journey

    I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

    Copyright © 2025 APAC CIOOutlook. All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Use and Privacy and Anti Spam Policy 

    Home |  CXO Insights |   Whitepapers |   Subscribe |   Conferences |   Sitemaps |   About us |   Advertise with us |   Editorial Policy |   Feedback Policy |  

    follow on linkedinfollow on twitter follow on rss
    This content is copyright protected

    However, if you would like to share the information in this article, you may use the link below:

    https://www.apacciooutlook.com/news/individualizing-drug-doses-amongst-patients-of-depression-nwid-4880.html